AbbVie scores speedy review for RA drug upadacitinib; Merck KGaA wins CRISPR patent
→ AbbVie $ABBV has high hopes, projecting peak potential sales of $6.5 billion, for its oral JAK1 inhibitor upadacitinib for rheumatoid arthritis, which is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
